SEC Filing Analysis: MAIA Biotechnology, Inc. (MAIA)

Executive Summary

• Trading Significance: Low
• Key Takeaway: Director Ramiro Guerrero purchased 37,595 shares on the open market at $1.3171 per share for a total investment of $49,516.37.
• Market Impact: Neutral given the small transaction size relative to total market capitalization.

Company Information

Field	Value
Company	MAIA Biotechnology, Inc.
Ticker Symbol	MAIA
CIK	0001878313
Industry	Pharmaceutical Preparations [2834]

Insider Information

Field	Value
Name	Guerrero Ramiro
CIK	0001913253
Title/Position	Director
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2026-09-10
Transaction Code	P (Purchase)
Security Type	Common Stock
Shares Involved	37,595
Price Per Share	$1.3171
Total Value	$49,516.37
Shares Owned After	773,296
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$49,516.37
% of Market Cap	0.062%
Shares Transacted	37,595
% of Shares Outstanding	0.062%
Post-Transaction Ownership	773,296 shares (1.27% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: Against MAIA's market capitalization of approximately $80 million (micro-cap tier), the ~$49.5K transaction size represents 0.062% of market cap.
• Ownership Concentration: The purchase expands the director's total holdings to 773,296 shares, representing 1.27% of total shares outstanding.
• Dilution Impact: None; this transaction was an open-market purchase, resulting in zero share dilution.
• Transaction Significance: Low significance under standard materiality thresholds (<0.1% of market cap and <0.1% of shares outstanding), though open-market purchases by board members reflect positive insider alignment.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: While direct insider purchases are fundamentally constructive, the total transaction value ($49.5K) is too modest to materially move share price or market sentiment.

Volume & Sentiment

• Expected Volume Impact: Negligible volume impact expected.
• Sentiment Indicator: Neutral

Additional Context

Transaction Notes

• Timing: Executed on September 10, 2026, and reported on September 14, 2026.
• Special Circumstances: The filing indicates no Rule 10b5-1 trading arrangement was utilized (aff10b5One = 0), indicating a discretionary open-market buy.
• Market Environment: Micro-cap clinical-stage biotechnology equities remain sensitive to pipeline catalysts and cash runway metrics.